Pilocytic astrocytoma is the most common pediatric brain tumor and commonly viewed as a benign lesion with excellent prognosis.^[@NOQ026C1]--[@NOQ026C4]^ Estimated 10-year survival rates range from 90% to 96.8%.^[@NOQ026C3],[@NOQ026C5]^ However, the 20-year survival and progression-free survival rates of approximately 70% and 40%, respectively,^[@NOQ026C6]--[@NOQ026C8]^ reflect the indolent nature of this disease. Furthermore, survivors of pilocytic astrocytomas commonly suffer long-term sequelae related to disease and treatment.^[@NOQ026C9]--[@NOQ026C13]^ Thus, a better understanding of pilocytic astrocytoma biology is needed to guide the development of new therapies to decrease morbidity and improve survival.

Hedgehog (Hh) signaling is one mechanism implicated in the growth of two other types of primary brain tumors, medulloblastoma and malignant glioma.^[@NOQ026C14],[@NOQ026C15]^ Additionally, recent limited clinical data indicate that targeted inhibition of the Hh pathway may be therapeutically beneficial for certain patients with medulloblastoma.^[@NOQ026C16]^ In a prior survey of WHO grade I--IV glioma specimens that included a small collection of pilocytic astrocytomas from adult patients, protein and transcript expression profiles for the Hh receptor Patched (PTCH) suggested that the Hh pathway might be activated to a small extent in this astrocytoma entity.^[@NOQ026C17]^ Therefore, in this study, we have investigated the Hh pathway in a larger panel of pilocytic astrocytoma specimens from pediatric patients. We demonstrate that the Hh pathway is operational in sporadic pilocytic astrocytomas and activated to a greater extent in tumors from younger patients. Furthermore, expression of the Hh pathway signal transduction components correlates with expression of the cellular proliferation marker Ki67.

Materials and Methods {#s2}
=====================

Tissue Procurement {#s2a}
------------------

Brain tumor and epilepsy specimens from patients treated at the Vanderbilt Medical Center from 2003 to 2008 were obtained in accordance with the Institutional Review Board\'s approval. Primary brain tumors were phenotyped and graded using the World Health Organization criteria,^[@NOQ026C18],[@NOQ026C19]^ and 20 specimens classified as pilocytic astrocytoma were used for these studies (Table [1](#NOQ026TB1){ref-type="table"}). Pilocytic astrocytoma patient ages ranged from 1 to 22 years, and patients with a diagnosis of neurofibromatosis type 1 and pilomyxoid astrocytoma were not included. The epilepsy control specimens were obtained from patients who were 37--57 years old. The locations of the pilocytic astrocytomas varied: 14 in the cerebellum, 2 in the midbrain, 1 in the temporal lobe, 1 in the frontal lobe, 1 in the thalamus, and 1 in the suprasellar region (Table [1](#NOQ026TB1){ref-type="table"}). RNA was extracted for quantitative real-time PCR (qRT-PCR) studies from 18 of the tumor specimens for which excess tissue was available for banking in a research tissue repository. Tissue cores were removed for tissue microarray construction from 17 of the tumor specimens that contained sufficient material in paraffin blocks. Primary cell cultures were generated from 4 of the tumor specimens for which adequate excess tissue was available. Table 1.Clinical and pathological features and the molecular analyses of pilocytic astrocytomasSampleAge (y)Primary/recurrentLocationPathologyPTCH RNAPTCH IHCGLI1 IHCKi67 IHC11.8PCerebellumPilomyxoid features2.309.010.290.1522.1PCerebellumInfiltration and oligodendroglioma-like5.724.670.790.3532.5PCerebellumInfiltration/pilomyxoid features11.515.156.900.1042.6PCerebellumClassic architecture3.566.292.381.0853.4PCerebellumInfiltration10.612.851.410.1264.1PSuprasellarPilomyxoid features and necrosis1.2532.1713.910.5574.7PMidbrain, exophyticPilomyxoid featuresNA6.542.730.0684.7PCerebellumInfiltration5.0128.2619.680.9395.3RMidbrain, exophyticPilomyxoid and oligodendroglioma-like features7.4224.0518.181.85106.7PCerebellum and midbrainPilomyxoid features and increased proliferation1.7236.5727.202.771113.7PCerebellumClassic architecture1.936.810.000.001214RCerebellumClassic architectureNA4.900.370.181314.3PCerebellumOligodendroglioma-like features3.80NANANA1414.8PCerebellumClassic architecture0.6713.394.170.061516.7PTemporal lobeClassic architecture1.03NANANA1618.3PCerebellumClassic architecture3.81NANANA1718.8PCerebellumClassic architecture0.820NANANA1820.1PFrontal lobeClassic architecture1.239.700.740.031921RCerebellum and suprasellarClassic architecture1.41NANANA2022PThalamusClassic architecture1.863.492.680.09[^2]

RNA Extraction, cDNA Synthesis, and qRT-PCR {#s2b}
-------------------------------------------

Total RNA was extracted from brain tissue or primary cell cultures with the RNeasy Mini Kit (QIAGEN). Genomic DNA was removed (RNase-Free DNase Set, QIAGEN) and purified RNA was quantified (RiboGreen RNA Quantitation Kit, Molecular Probes). Single-stranded cDNA was synthesized with oligo(dT) and random hexamer primers (iScript cDNA Synthesis Kit, Bio-Rad). For negative controls, reverse transcriptase was omitted from the synthesis reaction (−RT). For all measurements, qRT-PCR was performed in triplicate for each sample and on the corresponding −RT control. For primary brain tumor and epilepsy specimens, qRT-PCR reactions were performed with SYBR Green Supermix (Bio-Rad), cDNA template, and 200 nM primers for PTCH and glyceraldehyde 3-phosphate dehydrogenase (GAPDH).^[@NOQ026C17]^ Additionally, measurements in primary brain tumors were corroborated using the TaqMan primers for PTCH (Hs00970979_m1) and GAPDH (Hs99999905_m1). For primary cell cultures, qRT-PCR reactions were performed with the TaqMan Fast Universal PCR Master Mix (Applied Biosystems), cDNA template, and primers (TaqMan Gene Expression Assay, Applied Biosystems) for hPTCH (Hs00970979_m1), hGLI1 (Hs00171790_m1), and hGAPDH (Hs99999905_m1), respectively.^[@NOQ026C15]^ For standard curves, qRT-PCR was performed on serial dilutions of a human cDNA mixture.^[@NOQ026C17]^ For each amplicon, quantities were determined according to the standard curve method (User Bulletin \#2, PE Applied Biosystems).

Tissue Microarray Construction and Immunohistochemical Analysis {#s2c}
---------------------------------------------------------------

Surgical pathology slides were reviewed (by T.W.A.) to identify tumor regions of interest and any normal brain structures. The slides were marked and delivered to the Vanderbilt Human Tissue Acquisition and Pathology Core to identify the corresponding regions on the formalin-fixed, paraffin-embedded donor blocks and construct a tissue microarray. Four tissue cores (1.0 mm diameter) were removed from each donor block, assigned a coded identifier, and manually placed in nonadjacent positions of the recipient microarray block. Twenty consecutive sections (5 µm) from the tissue microarray were mounted on silanized slides. Sections 1 and 20 were stained with hematoxylin and eosin to confirm sample integrity, and sections 2--19 were used for the immunohistochemical analysis.

Immunohistochemistry was performed with the following antibodies: PTCH-1 (1:100; Santa Cruz Biotechnologies), Ki67 (1:50; DAKO), Bmi-1 (1:100; Upstate), and Gli-1 (1:50; Cell Signaling). The slides were deparaffinized and microwaved in a citrate buffer (pH 6.0) for antigen retrieval. They were treated with 3% hydrogen peroxide solution, incubated in blocking serum, and incubated in primary antibody overnight at 4°C. Biotinylated secondary antibody was incubated overnight at 4°C, and immunodetection with 3,3′-diaminobenzidine or 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) substrate was performed using the Vectastain Elite ABC kit (Vector Laboratories).

Staining indices for each sample on the microarray were determined by dividing the average number of cells that stained positively for PTCH, GLI1, or Ki67 per high-power microscopic fields (hpf) by the total number of cells per hpf. Cells staining for PTCH, GLI1, and Ki67 were counted in 9 hpf for each sample on the single-antibody--labeled slides. The total numbers of cells were counted in 4 hpf for each sample on a slide stained with hematoxylin. Depending on tissue integrity, values for each tumor were obtained from at least 2 samples on every microarray slide. Tumor identity was determined only after the staining was scored.

Cell Culture and Hh Signaling Assays {#s2d}
------------------------------------

Tumor samples were dissociated (Papain, Worthington Biochemical Corporation) and plated in DMEM/F12, 10% FBS, and 1× penicillin--streptomycin (Invitrogen). After primary cell cultures reached confluency, they were plated for 7 days in nontreated polystyrene flasks (BD-Falcon) in NeuroCult medium with supplements (NeuroCult NS-A Proliferation Kit; Stem Cell Technologies), 2 µg/mL heparin (Sigma), 20 ng/mL EGF (ProSpec-Tany TechnoGene), 10 ng/mL bFGF (ProSpec-Tany TechnoGene), and 1× penicillin-streptomycin (Invitrogen). The resulting spheres of cells were transferred to nontreated polystyrene multiwell plates (BD-Falcon) and cultured in triplicate for 40 hours either alone, with 50 nM smoothened agonist (SAG), with 500 nM SAG, or with 200 nM smoothened antagonist (SANT1). For assays of Hh pathway inhibition, confluent cultures were plated in nontreated polystyrene flasks (BD-Falcon) in NeuroCult medium with supplements (NeuroCult NS-A Proliferation Kit; Stem Cell Technologies), 2 µg/mL heparin (Sigma), 1× penicillin--streptomycin (Invitrogen), and 50 nM SAG. The resulting spheres of cells were transferred to multiwell plates and cultured in triplicate for 48 hours either with 50 nM SAG or with 200 nM SANT1. GLI1 and GAPDH levels were measured by qRT-PCR as described above.

Statistical Analysis {#s2e}
--------------------

To measure the correlation between two variables, the Pearson product--moment correlation coefficient was calculated with a 99% confidence interval (GraphPad Prism). Student\'s *t*-test was used to compare the mean values from the 2 groups.

Results {#s3}
=======

PTCH mRNA Expression Levels in Pilocytic Astrocytomas Correlate Inversely with Age {#s3a}
----------------------------------------------------------------------------------

To evaluate the Hh pathway activity, PTCH mRNA levels were measured by qRT-PCR in 18 of the pilocytic astrocytomas evaluated in this study (Table [1](#NOQ026TB1){ref-type="table"}) and in 3 specimens from patients with epilepsy (Fig. [1](#NOQ026F1){ref-type="fig"}). PTCH is a signal transduction component and direct gene target of Hh signaling, whose expression level can serve as a metric for pathway activity.^[@NOQ026C20],[@NOQ026C21]^ For all samples, PTCH levels were normalized to endogenous GAPDH levels and expressed as the fold difference relative to control samples resected from patients with epilepsy. Compared with control specimens, PTCH RNA expression was elevated in 45% of the pilocytic astrocytoma specimens (Fig. [1](#NOQ026F1){ref-type="fig"}). A significant inverse correlation between PTCH expression levels and patient age (Pearson\'s test, *r* = −.59, *P* = .0097) suggests that the Hh pathway may be activated in pilocytic astrocytomas from younger patients. When grouped according to diagnosis before and after the median patient age of 10, median PTCH levels were 5.01 and 1.23, respectively (Student\'s *t*-test, *P* = .013; Fig. [2](#NOQ026F2){ref-type="fig"}A).

![PTCH mRNA expression in pilocytic astrocytomas. Graphic illustration of the relative PTCH expression levels from samples listed in Table [1](#NOQ026TB1){ref-type="table"} revealed a significant inverse correlation with patient age (Pearson\'s test, *r* = −.59, *P* = .0097).](noq02601){#NOQ026F1}

![Comparison of age at diagnosis and molecular analyses of Hedgehog pathway activation. (A) When grouped according to diagnosis before and after the age of 10 years, median PTCH levels are 5.01 and 1.23, respectively (Student\'s *t*-test, *P* = .013). (B and C) Higher staining indices for PTCH and GLI1 are measured in tumors from younger patients. In specimens from patients diagnosed before and after the age of 10, the median values for PTCH are 14.00 and 6.81, respectively (Student\'s *t*-test, *P* = .033; B) and for GLI1 they are 4.82 and 0.74 (Student\'s *t*-test, *P* = .034; C).](noq02602){#NOQ026F2}

PTCH and GLI1 Protein Staining Indices in Pilocytic Astrocytomas Correlate with that of a Cellular Marker for Proliferation {#s3b}
---------------------------------------------------------------------------------------------------------------------------

To corroborate these findings, pathological features of the 20 pilocytic astrocytoma specimens (Table [1](#NOQ026TB1){ref-type="table"}) were reviewed for tissue microarray construction. Compact growth patterns and biphasic architectural organizational patterns predominated in all specimens. However, 9 of the patient samples demonstrated at least one additional histological feature that included oligodendroglioma-like qualities, pilomyxoid features, leptomeningeal spread, focal areas of increased proliferation, necrosis, or focal infiltrative growth (Fig. [3](#NOQ026F3){ref-type="fig"}). These pathological features were more prevalent in patients diagnosed with pilocytic astrocytoma before the age of 10 (Table [1](#NOQ026TB1){ref-type="table"}), and several have been associated with poorer outcome.^[@NOQ026C4],[@NOQ026C22]--[@NOQ026C24]^ Four tissue cores from 17 of the donor paraffin blocks that contained sufficient material were included in a recipient microarray block. Immunohistochemistry was performed for the Hh receptor PTCH and the Hh transcription factor GLI1, and staining was scored in an investigator-blinded fashion. Adequate tissue for the immunohistochemical analysis was available for 15 of the 17 tumors on the tissue microarray sections.

![Putative aggressive pathological features in pilocytic astrocytoma specimens. (A--F) Putative aggressive features noted on review of 20 anonymized pilocytic astrocytoma specimens. Tumor infiltration demonstrated by entrapped neuronal cell bodies (arrowhead in A) and axons coursing through the neoplasm (arrowhead in B, neurofilament stain), oligodendroglioma-like features (C), pilomyxoid features (arrowheads in D), leptomeningeal spread (arrowheads in E), and necrosis (arrowhead in F) were noted in 9 of the patient samples. These pathological features were more prevalent in patients diagnosed prior to the age of 10 (Table [1](#NOQ026TB1){ref-type="table"}). Scale bar indicates 50 µm in A and B, 100 µm in C and D, and 500 µm in E and F.](noq02603){#NOQ026F3}

Single-label staining for PTCH or GLI1 produced concordant results for each donor tissue core, with greater numbers of cells labeled for PTCH than GLI1 in all instances (Fig. [4](#NOQ026F4){ref-type="fig"} and [Supplementary Material, Fig. S1](http://neuro-oncology.oxfordjournals.org/cgi/content/full/noq026/DC1)). A notable feature of this type of analysis was variability in PTCH or GLI1 staining indices among some of the tissue cores sampled from the same tumor ([Supplementary Material, Table S1 and Fig. S2](http://neuro-oncology.oxfordjournals.org/cgi/content/full/noq026/DC1)). This suggests that pilocytic astrocytomas are heterogeneous with respect to Hh pathway component expression. Consistent with this interpretation, the PTCH or GLI1 staining indices from one portion of a tumor did not always correspond with the PTCH mRNA expression level measured in another portion of the same tumor (Table [1](#NOQ026TB1){ref-type="table"}). However, as for PTCH mRNA measurements, higher staining indices for PTCH and GLI1 were measured in tumors from younger patients (Fig. [2](#NOQ026F2){ref-type="fig"}). In specimens from patients diagnosed before and after the age of 10, the median values for PTCH were 14.00 and 6.81, respectively (Student\'s *t*-test, *P* = .033; Fig. [2](#NOQ026F2){ref-type="fig"}B), and for GLI1 they were 4.82 and 0.74 (Student\'s *t*-test, *P* = .034; Fig. [2](#NOQ026F2){ref-type="fig"}C).

![Hedgehog pathway component expression in a pilocytic astrocytoma specimens. (A--C) Representative image of a pilocytic astrocytoma from a tissue microarray stained with hematoxylin and eosin (A) and for GLI1 (arrowheads in B), and PTCH and Ki67 (C). Arrowhead in C demonstrates a PTCH^+^/Ki67^+^ cells. Scale bar = 50 µm.](noq02604){#NOQ026F4}

To evaluate cellular proliferation, Ki67 immunohistochemistry was performed with the pilocytic astrocytoma tissue microarray. Consistent with other reports, Ki67 labeling indices ranged from 0% to 2.77% and were higher in younger patients (Table [1](#NOQ026TB1){ref-type="table"}).^[@NOQ026C25],[@NOQ026C26]^ In addition, a significant correlation between Ki67 and PTCH (Pearson\'s test, *r* = .68, *P* = .0058) and between Ki67 and GLI1 (Pearson\'s test, *r* = .82, *P* = .0002) staining indices was measured. To corroborate these observations, double-labeling experiments were performed and revealed that 86% of Ki67-positive cells expressed PTCH across all tumors (Fig. [4](#NOQ026F4){ref-type="fig"}C and data not shown).

Hh Pathway Modulation Can Be Measured in Primary Cells Cultured from Pilocytic Astrocytomas {#s3c}
-------------------------------------------------------------------------------------------

In order to assess the operational status of the Hh pathway, primary cell cultures were generated from 4 pilocytic astrocytomas (sample numbers 6, 10, 15, and 18; Table [1](#NOQ026TB1){ref-type="table"}) and 2 higher-grade adult astrocytomas that served as controls. Under culture conditions that are required for eliciting an Hh pathway response,^[@NOQ026C17]^ the addition of an SAG (50 nM) induced a significant increase in GLI1 mRNA expression in 2 of the 4 pilocytic astrocytoma cultures (sample numbers 6 and 18; *P* \< .05, Student\'s *t*-test; Fig. [5](#NOQ026F5){ref-type="fig"}A). The basal expression levels of GLI1 transcript were not reduced by treatment with a SANT1 (200 nM)^[@NOQ026C27]^ in any of the astrocytoma cultures (Fig. [5](#NOQ026F5){ref-type="fig"}A). The levels of GLI1 induction in the pilocytic astrocytoma cultures were comparable to those observed in a Hh-responsive WHO grade II astrocytoma control culture (Fig. [5](#NOQ026F5){ref-type="fig"}A). Consistent with prior studies, GLI1 expression levels were not induced by the SAG treatment of a primary GBM culture that served as a negative control in the analysis.^[@NOQ026C15],[@NOQ026C17]^ The findings from this survey of 4 tumors provide evidence that the Hh pathway is operationally intact within a subset of pilocytic astrocytomas.

![Characterization of Hedgehog pathway responsiveness in primary cell cultures from pilocytic astrocytomas. (A) Astrocytic tumors were grown as spheres under stem cell culture conditions. Cells from a Hh-responsive astrocytoma (GII A), a Hh-unresponsive GBM (GIV GBM), and 4 pilocytic astrocytomas (GI PA-6, GI PA-10, GI PA-15, and GI PA-18) were cultured for 36 hours either alone (control), with 50 nM SAG, or with 200 nM SANT1. In triplicate wells for each cell line and culture condition, the GLI1 levels were normalized to GAPDH and expressed relative to the untreated control cultures. (B) To confirm a dose-dependent response to Hh pathway stimulation, the GI PA-18 cells were cultured in triplicate wells either alone (control), with 50 nM SAG, or with 200 nM SAG. After 40 hours, the GLI1 levels were normalized to GAPDH and expressed relative to the untreated control cultures. (C) To determine whether Hh signaling could be inhibited following pathway activation, the GI PA-18 cells were cultured in the presence of SAG (50 nM) for 7 days and then re-plated in triplicate wells containing either 50 nM SAG or 200 nM SANT1. After an additional 48 hours in culture, the GLI1 levels were normalized to GAPDH and expressed relative to the SAG-treated cultures. GI, WHO grade I; GII, WHO grade II; GIV, WHO grade IV; A, astrocytoma; AA, anaplastic astrocytoma; GBM, glioblastoma multiforme; PA, pilocytic astrocytoma; SAG, smoothened agonist; SANT, smoothened antagonist; \**P* ≤ .05.](noq02605){#NOQ026F5}

To confirm the modulatory status of the Hh pathway, dose-dependent induction of GLI1 mRNA with SAG was assayed (Fig. [5](#NOQ026F5){ref-type="fig"}B). To determine whether once activated the pathway could then be inhibited, a culture was generated in the presence of SAG. After 7 days, a portion of the spheres from the parent culture was re-plated in the presence of SANT1. The GLI1 levels were elevated in the parent culture derived in the presence of SAG and could be reduced to basal levels by SANT1 treatment (Fig. [5](#NOQ026F5){ref-type="fig"}C). These data demonstrate that Hh signaling in a pilocytic astrocytoma primary culture can be modulated by either activation or inhibition, thereby confirming the operational status of the pathway.

Discussion {#s4}
==========

A role for aberrant Hh signaling in tumorigenesis was first appreciated with the discovery that the autosomal dominant disorder, Gorlin\'s syndrome, is associated with mutations in the *PTCH* gene.^[@NOQ026C28],[@NOQ026C29]^ Patients with Gorlin\'s syndrome (also called basal cell nevus syndrome) display an increased incidence of basal cell carcinoma and medulloblastoma. Since that time, mutations in *PTCH*,^[@NOQ026C30]--[@NOQ026C32]^ *Smoothened* (*SMOH*),^[@NOQ026C33],[@NOQ026C34]^ or *Suppressor-of-Fused* (*SUFU*)^[@NOQ026C35]^ have been identified in approximately 30% of sporadic medulloblastoma specimens. Mutations in these 3 Hh components confer "ligand-independent" activation of the pathway. In contrast, "ligand-dependent" activation of the Hh pathway has been identified in a broader array of malignancies^[@NOQ026C36]^ including a subset of malignant gliomas.^[@NOQ026C17],[@NOQ026C37]--[@NOQ026C39]^ Here, we show ligand-dependent activation of the Hh pathway in a subset of pilocytic astrocytomas, low-grade gliomas that are clinically and genetically distinct from malignant gliomas.

Hh signaling in primary brain tumors and the divergent mechanisms by which the pathway is activated illustrate several features that are pertinent to the findings in this study. First, the incidence of Hh pathway activation in sporadic medulloblastomas can be defined with greater precision by mutational analysis. In the case of gliomas, the proportion of tumors in which the pathway is activated is less well defined in the absence of clear thresholds for PTCH and GLI1 expression levels to define an "on" or "off" state. Second, in contrast to medulloblastomas, in which clonal deregulation of Hh signaling is driven by mutations in the pathway, marked cellular heterogeneity in the expression of Hh pathway components suggests that the Hh pathway is activated in only a portion of tumor cells in malignancies with a ligand-dependent mechanism of activation. Lastly, a requirement for the Hh pathway activity in the growth of medulloblastomas and malignant gliomas has been demonstrated in animal transplantation models.^[@NOQ026C14],[@NOQ026C15]^

In these studies, we demonstrate that the Hh pathway is activated in a subset of pilocytic astrocytomas. Complementary methods to assess the expression of the Hh pathway components and gene targets PTCH and GLI1 were utilized, and multiple regions of the same tumor were sampled. Pilocytic astrocytomas are characterized by marked heterogeneity in cytoarchitecture and patterns of cellular organization. With regard to PTCH and GLI1 expression, we find that levels vary with respect to the portion of tumor sampled. Signaling assays with primary cell cultures confirm that the Hh pathway is operational in pilocytic astrocytomas. The Hh pathway could be modulated in only a subset of primary cell cultures, consistent with heterogeneity in either the operational status of the pathway or the portion of tumor selected for culture. The ability to significantly induce GLI1 mRNA with SAG combined with the inability to inhibit the basal GLI1 levels with an antagonist suggests that Hh signaling is not constitutively activated.^[@NOQ026C27],[@NOQ026C40]^ Therefore, as in WHO grade II and III gliomas, the Hh pathway appears to be activated in a ligand-dependent manner in pilocytic astrocytomas.^[@NOQ026C15],[@NOQ026C17]^ A role for Hh signaling in pilocytic astrocytomas cannot be determined in the absence of animal models for sporadic disease. However, a notable feature of our studies is the demonstration of a significant correlation between Ki67 and PTCH and GLI1 staining. This finding suggests that, as for other primary brain tumor types,^[@NOQ026C14],[@NOQ026C15]^ Hh signaling may regulate the growth of pilocytic astrocytomas.

Combined with the prior measurements of low PTCH expression in adult pilocytic astrocytomas,^[@NOQ026C17]^ the inverse correlation between PTCH mRNA and patient age in this study suggests that the Hh pathway may be activated to a greater extent in younger patients. Although some studies suggest that younger age at diagnosis portends shorter progression-free survival,^[@NOQ026C41],[@NOQ026C42]^ this has not been validated by other series.^[@NOQ026C1],[@NOQ026C4],[@NOQ026C43]^ Additionally, we observed that potentially aggressive histological features were more commonly associated with tumors from younger patients. In particular, some series suggest that necrosis, oligodendroglioma-like features, and infiltrative growth are associated with decreased event-free survival.^[@NOQ026C4],[@NOQ026C24]^ Evaluation of a larger series of tumor samples will be required to determine if the Hh pathway is activated to a greater extent in pilocytic astrocytomas from younger patients and whether this correlates with specific histopathologic features and tumor progression.

Recent findings implicate aberrant activation of the MAPK pathway, due to *BRAF* gene rearrangements or mutations, in 66%--85% of sporadic pilocytic astrocytomas.^[@NOQ026C44]--[@NOQ026C47]^ Integration of MAPK and Hh signaling, by ERK-mediated control of the GLI function, has been implicated in the regulation of cellular proliferation in basal cell and gastric carcinomas.^[@NOQ026C48]--[@NOQ026C50]^ Whether the MAPK and the Hh pathways function synergistically to regulate the growth of pilocytic astrocytomas warrants further study. In this respect, there remains an important need for animal models of sporadic pilocytic astrocytomas.
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======================
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